Home | Myriad Genetics - When Decisions Matter
  • Patients
    • Patient Questions
      • What’s My Risk?
      • Do I Have A Disease?
      • How Aggressive is My Disease?
      • How Should I Treat My Disease?
    • Genetic Testing 101
      • Genes & Disease
      • Benefits of Genetic Testing
      • Genetic Testing FAQs
      • Real Patient Stories
    • Resources
      • Hereditary Cancer Quiz
      • Women’s Health Resources
      • Depression Resources
      • Oncology Resources
      • Melanoma Resources
      • Rheumatoid Arthritis Resources
      • Prostate Cancer Resources
    • Affordability
      • The Myriad Promise
      • Financial Assistance Program
  • Providers
    • Patient Care
      • Predicting Disease
      • Diagnosing Disease
      • Assessing Prognosis
      • Precision Medicine
      • Genetic Testing Process
    • Resources
      • MyriadPro™
      • Hereditary Cancer Quiz
      • Order a Test Kit
      • Lab Certificates
      • MyVision
  • Products
    • Myriad Products
      • Breast Cancer
        • EndoPredict®
      • Carrier Screen
        • Foresight®
      • Depression
        • GeneSight®
      • Melanoma
        • myPath®
      • Hereditary Cancers
        • myRisk®
        • riskScore®
        • BRACAnalysis®
        • COLARIS®
        • COLARIS AP®
      • Precision Medicine
        • BRACAnalysis CDx®
        • myChoice® CDx
      • Prenatal Screen
        • PrequelTM
      • Prostate Cancer
        • Prolaris®
      • Rheumatoid Arthritis
        • Vectra®
  • About
    • Company
      • About Myriad Genetics
      • Company Fact Sheet
      • History
      • Executive Team
      • Board of Directors
    • Global Presence
      • Myriad International
      • Myriad Japan
    • Myriad Cares
      • Corporate Social Responsibility
      • Patient Advocacy
      • Policy on Genetic Information
  • Contact
    • Offices
      • Corporate Offices
      • International Offices
    • Divisions
      • Billing
      • Customer Service
      • International
      • Medical Records
      • Medical Services
      • Myriad Autoimmune
      • Myriad Neuroscience
      • Myriad Women’s Health
      • Myriad RBM
    • Address
      • Myriad Genetics, Inc.
        320 Wakara Way
        Salt Lake City, UT 84108
    • Phone
      • (800) 4-MYRIAD
      • (800) 469-7423
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Patients
    • Patient Questions
      • What’s My Risk?
      • Do I Have A Disease?
      • How Aggressive is My Disease?
      • How Should I Treat My Disease?
    • Genetic Testing 101
      • Genes & Disease
      • Benefits of Genetic Testing
      • Genetic Testing FAQs
      • Real Patient Stories
    • Resources
      • Hereditary Cancer Quiz
      • Women’s Health Resources
      • Depression Resources
      • Oncology Resources
      • Melanoma Resources
      • Rheumatoid Arthritis Resources
      • Prostate Cancer Resources
    • Affordability
      • The Myriad Promise
      • Financial Assistance Program
  • Providers
    • Patient Care
      • Predicting Disease
      • Diagnosing Disease
      • Assessing Prognosis
      • Precision Medicine
      • Genetic Testing Process
    • Resources
      • MyriadPro™
      • Hereditary Cancer Quiz
      • Order a Test Kit
      • Lab Certificates
      • MyVision
  • Products
    • Myriad Products
      • Breast Cancer
        • EndoPredict®
      • Carrier Screen
        • Foresight®
      • Depression
        • GeneSight®
      • Melanoma
        • myPath®
      • Hereditary Cancers
        • myRisk®
        • riskScore®
        • BRACAnalysis®
        • COLARIS®
        • COLARIS AP®
      • Precision Medicine
        • BRACAnalysis CDx®
        • myChoice® CDx
      • Prenatal Screen
        • PrequelTM
      • Prostate Cancer
        • Prolaris®
      • Rheumatoid Arthritis
        • Vectra®
  • About
    • Company
      • About Myriad Genetics
      • Company Fact Sheet
      • History
      • Executive Team
      • Board of Directors
    • Global Presence
      • Myriad International
      • Myriad Japan
    • Myriad Cares
      • Corporate Social Responsibility
      • Patient Advocacy
      • Policy on Genetic Information
  • Contact
    • Offices
      • Corporate Offices
      • International Offices
    • Divisions
      • Billing
      • Customer Service
      • International
      • Medical Records
      • Medical Services
      • Myriad Autoimmune
      • Myriad Neuroscience
      • Myriad Women’s Health
      • Myriad RBM
    • Address
      • Myriad Genetics, Inc.
        320 Wakara Way
        Salt Lake City, UT 84108
    • Phone
      • (800) 4-MYRIAD
      • (800) 469-7423
Investors > News Releases

News Releases

Feb 12, 2021
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer
Pipeline
Jan 08, 2021
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®
Products
Dec 11, 2020
New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations
Pipeline
Nov 16, 2020
Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
Pipeline
Nov 11, 2020
New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis
Pipeline
Oct 16, 2020
German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test
Pipeline
Aug 21, 2020
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
Pipeline
Aug 10, 2020
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions
Pipeline
Jul 31, 2020
Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer
Pipeline
Jul 29, 2020
Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test
Pipeline
Jul 28, 2020
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®
Pipeline
Jul 07, 2020
Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction
Products
Jul 01, 2020
Myriad Launches New GeneSight® Psychotropic Patient Collection Kit
Products
Jun 25, 2020
New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment
Pipeline
Jun 15, 2020
Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider
Products
Next page
  • Payers
  • Overview
  • Clinical Data
  • Health Economics
  • Medical Guidelines
  • Coverage + Billing
  • Payer News
  • Partners
  • Research
  • Companion Diagnostics
  • Academic Collaborations
  • Licensing
  • Investors
  • Financial Reporting
  • Stock Information
  • Events + Presentations
  • Investor FAQs
  • News
  • Press Releases
  • Myriad Genetics Blog
  • Company Logos
  • Career
  • Joining the Team
Myriad Genetics Logo
  • Terms of Use
  • Privacy Policy
  • Language Assistance
© 2021 Myriad Genetics, Inc.

Website Feedback








reCAPTCHA helps prevent automated form spam.
The submit button will be disabled until you complete the CAPTCHA.

Contact Information